ASKC202 is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Registered phases: Phase 1 and Phase 3. Conditions studied include Advanced Solid Tumor; Locally Advanced or Metastatic NSCLC.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07109531 | ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy (ClinicalTrials.gov ↗) Locally Advanced or Metastatic NSCLC |
Phase 3 | Recruiting |
| NCT05306132 | Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 (ClinicalTrials.gov ↗) Advanced Solid Tumor |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Solid Tumor | 1 |
| Locally Advanced or Metastatic NSCLC | 1 |
| Lead sponsor | Trials |
|---|---|
| Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 2 |
| Register | ASKC202 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ASKC202 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ASKC202 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.